Autologous CAR-T Cells (WD-01) for Metastatic Colorectal Cancer

This study is testing a custom CAR-T cell therapy called WD-01 for patients with metastatic colorectal cancer that has stopped responding to standard treatments. CAR-T therapy involves taking a patient's own immune cells, engineering them in a lab to recognize and attack cancer, and then infusing them back. **You may be eligible if...** - You have confirmed colorectal cancer that has spread (metastatic) - Your tumor cells express a protein called GCC on at least 40% of the tumor area - Your cancer has failed at least two lines of prior treatment - You have at least one measurable tumor outside the brain - Your expected survival is at least 90 days and your general health and organ function are adequate **You may NOT be eligible if...** - Your cancer does not express the GCC target protein at sufficient levels - You have active autoimmune disease or other serious conditions that make CAR-T therapy unsafe - Your blood counts or organ function are too low to tolerate the treatment Talk to your doctor to see if this trial is right for you.